Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

April 7, 2020

Takeda gets EU approval for ALUNBRIG in ALK+ NSCLC

Takeda Pharmaceutical has secured expanded approval for ALUNBRIG (brigatinib) in the European Union (EU) to use the tyrosine kinase inhibitor for the treatment of a particular lung cancer population.

Takeda gets EU approval for ALUNBRIG in ALK+ NSCLC